The online version of this article (doi:10.1186/1477-7819-10-203) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interests.
EPM and DKA gathered and compiled data and have been involved in drafting the manuscript. AJN and STL participated in the design of the study and performed the statistical analysis. ACS and MS revised the manuscript critically for important intellectual content. MS and MFD have given final approval of the version to be published. All authors read and approved the final manuscript.
Recent studies have demonstrated that pathological analysis of retroperitoneal residual masses of patients with testicular germ cell tumors revealed findings of necrotic debris or fibrosis in up to 50% of patients. We aimed at pursuing a clinical and pathological review of patients undergoing post chemotherapy retroperitoneal lymph node dissection (PC-RPLND) in order to identify variables that may help predict necrosis in the retroperitoneum.
We performed a retrospective analysis of all patients who underwent PC-RPLND at the University Hospital of the University of São Paulo and Cancer Institute of Sao Paulo between January 2005 and September 2011. Clinical and pathological data were obtained and consisted basically of: measures of retroperitoneal masses, histology of the orchiectomy specimen, serum tumor marker and retroperitoneal nodal size before and after chemotherapy.
We gathered a total of 32 patients with a mean age of 29.7; pathological analysis in our series demonstrated that 15 (47%) had necrosis in residual retroperitoneal masses, 15 had teratoma (47%) and 2 (6.4%) had viable germ cell tumors (GCT). The mean size of the retroperitoneal mass was 4.94 cm in our sample, without a difference between the groups (P = 0.176). From all studied variables, relative changes in retroperitoneal lymph node size (P = 0.04), the absence of teratoma in the orchiectomy specimen (P = 0.03) and the presence of choriocarcinoma in the testicular analysis after orchiectomy (P = 0.03) were statistically significant predictors of the presence of necrosis. A reduction level of 35% was therefore suggested to be the best cutoff for predicting the absence of tumor in the retroperitoneum with a sensitivity of 73.3% and specificity of 82.4%.
Even though retroperitoneal lymph node dissection remains the gold standard for patients with residual masses, those without teratoma in the primary tumor and a shrinkage of 35% or more in retroperitoneal mass have a considerably smaller chance of having viable GCT or teratoma in the retroperitoneum and a surveillance program could be considered.
Authors’ original file for figure 112957_2011_1125_MOESM1_ESM.jpeg
Foster R, Bihrle R: Current status of retroperitoneal lymph node dissection and testicular cancer: when to operate. Cancer Control. 2002, 9: 277-283. PubMed
Steyerberg EW, Keizer HJ, Fossa SD, Sleijfer DT, Toner GC, SchraffordtKoops H, Mulders PF, Messemer JE, Ney K, Donohue JP: Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995, 13: 1177-1187. PubMed
Tait D, Peckham MJ, Hendry WF, Goldstraw P: Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer. 1984, 50: 601-609. 10.1038/bjc.1984.226. PubMedCentralCrossRefPubMed
Fizazi K, Tjulandin S, Salvioni R, Germà-Lluch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Fléchon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Théodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahé C: Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy–results from an international study group. J Clin Oncol. 2001, 19: 2647-2657. PubMed
Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, de Wit M: European consensus on diagnosis and treatment of germ cell cancer: a report of the European germ cell cancer consensus group (EGCCCG). Ann Oncol. 2004, 15: 1377-1399. 10.1093/annonc/mdh301. CrossRefPubMed
Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG, Einhorn L, Williams S, Loehrer P: Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol. 1987, 137: 1176-1179. PubMed
Nicolai N, Miceli R, Artusi R, Piva L, Pizzocaro G, Salvioni R: A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol. 2004, 171: 172-176. 10.1097/01.ju.0000101513.64777.f2. CrossRefPubMed
Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE: Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?. J Clin Oncol. 1992, 10: 569-573. PubMed
- Predicting necrosis in residual mass analysis after retroperitoneal lymph node dissection: a retrospective study
Eduardo de Paula Miranda
Daniel Kanda Abe
Adriano João Nesrallah
Sabrina Thalita dos Reis
Marcos Francisco Dall’Oglio
- BioMed Central
Neu im Fachgebiet Chirurgie
Mail Icon II